Revised. Amendments from Version 1
==================================

Description of main differences between the two versions The following revisions have been made in the revised version in response to the reviewer's comments We have clarified in the inclusion/exclusion criteria that the eligible studies were not filtered by study settings. We have noted in the discussion section that the different methods of assessment of neurological and mental manifestations in individual eligible studies may have contributed to the heterogeneity of pooled estimates observed during the analysis which informed our decision to apply the random effect model rather than the fixed effect model. The random effect model allows the prevalence of mental and neurological manifestations varies from one study to the next. We have noted in the limitation section that a quality check on all eligible studies was performed which may have excluded a number of children studies. We already described in the methods section of first version that the quality check was based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system for experimental studies and The Joanna Briggs Institute Prevalence Critical Appraisal Tool for observation studies..  We have now noted in the discussion session that the very high between study heterogeneity observed may be partly explained by factors not reported in the included studies such as levels of endemicity of malaria in the study sites and individual factors such as resistance to malaria, as suggested by the reviewer.

Introduction
============

Over 3.2 billion people in the world are at risk of malaria (Malaria fact sheet, World Health Organization) and a wide range of antimalarial drugs is used to prevent and treat malaria. Malaria continues to be a major cause of morbidity and mortality, but both have declined with the introduction of effective anti-malarial drugs malaria (Malaria fact sheet, World Health Organization). Mental and neurological manifestations are common in patients with malaria, particularly children admitted to hospital with falciparum malaria in Africa ^[@ref-1],\ [@ref-2]^. Survivors of severe malaria develop a wide range of neuro-cognitive sequelae, including epilepsy, language deficits, motor and sensory deficits, and other neurobehavioral difficulties ^[@ref-3],\ [@ref-4]^. Antimalarial drugs are thought to have significant mental and neurological manifestations ^[@ref-5]--\ [@ref-7]^. Antimalarials prescribed to prevent malaria are associated with mental and neurological manifestations, some of which are similar to the manifestations seen in acute malaria ^[@ref-8]--\ [@ref-10]^. Therefore, the neuro-cognitive and behavioural sequelae observed after malaria may be related to the underlying malarial illness or the antimalarial drugs. Teratogenicity is reported after the use of antimalarial drugs in pregnancy, but mental and neurological damage is not extensively studied ^[@ref-11]^.

Mental and neurological manifestations of antimalarial drugs are observed in both animals and humans ^[@ref-8],\ [@ref-12]--\ [@ref-18]^. Animal studies identify potential mechanisms of mental and neurological manifestations and the parts of the central nervous system (CNS) affected. To date, there have been no human studies attempting to explore the role that drugs play in causing mental and neurological manifestations after accounting for the malarial illness, although some studies have acknowledged that malaria illness alone cannot explain neuro-cognitive and behavioural sequelae observed after treatment ^[@ref-4]^. Reports have highlighted severe neuropsychiatric reactions after use of mefloquine for prophylaxis ^[@ref-19],\ [@ref-20]^, but properly designed studies are required to quantify and clarify the extent of these manifestations. Studying the use of antimalarial drugs for prophylaxis can help to estimate the prevalence of mental and neurological manifestations in non-infected subjects, and compare with the prevalence observed in patients with malaria to understand if antimalarial drugs add to mental and neurological manifestations.

We conducted a systematic review and meta-analysis of the published literature on mental and neurological manifestations associated with antimalarial drugs, and reported the findings according to the PRISMA guidelines ^[@ref-21]^. We estimated the pooled overall prevalence of mental and neurological outcomes among the human studies identified and examined if prevalence differed by type and number of antimalarial drugs used. We also investigated and quantified the sources of heterogeneity between the studies and attempted to identify the factors explaining the variation in prevalence of mental and neurological outcomes.

Methods
=======

Information sources
-------------------

We searched the following online databases systematically: MEDLINE, EMBASE, CINHL, PsycINFO, Central Registration for Clinical Trials, Open Grey Database, Canadian Agency for Drugs and Technologies in Health, Directory of Open-Access Repository, World Cat database, and Web of Science. Reference lists of identified articles were also searched for relevant titles and these were in turn searched online. All authors contributed to the search strategy. Consensus was used to set the selection criteria according to recommendations ^[@ref-22]^.

Search strategies
-----------------

An initial limited search of MEDLINE, COCHRANE LIBRARY and EMBASE was undertaken followed by analysis of the text words contained in the title and abstract, and of the index terms used to describe articles. Combined text words and Medical Subject Headings (MeSH) terminology were used in addition to the two main search terms/facets \[Mental and neurological and Antimalarial Drugs\] ( [Supplementary Table 1](#SM1){ref-type="supplementary-material"}). Boolean operators, such as "AND" and "OR", were used to combine search terms as necessary. Truncation, wildcard, adjacent searching, and floating subheadings were also used to increase the sensitivity of the results in unpublished data, where necessary. The construction of search terms followed the recommendations by the National Health Service Centre for Reviews and Disseminations.

Inclusion and exclusion criteria
--------------------------------

We included studies that met the following criteria: (i) use of an antimalarial agent ( [Table 1](#T1){ref-type="table"}) (either as a prophylactic drug or as treatment for malaria or another illness); and (ii) report of mental and neurological symptoms, including psychiatric disorders, cognitive impairments, sensory problems, and seizures (during or after using the antimalarial) ( [Table 2](#T2){ref-type="table"}). We also included studies reporting foetal teratogenicity following use of antimalarial drug in pregnancy. Only empirical studies were considered for the main analysis, while case series/reports studies were excluded because their findings cannot be generalized. There was no restriction on age of the participants or on the study settings.

###### Classification of antimalarial drugs.

  ------------------------------------------------------------------
  Class                     Drugs
  ------------------------- ----------------------------------------
  4-Aminoquinolines         Chloroquine,\
                            amodiaquine, hydroxychloroquine

  8-Aminoquinoline          Primaquine, pamaquine, pentaquine,\
                            isopentaquine

  4-quinolinemethanols      Quinine, quinidine, mefloquine

  Phenanthrene methanol     Halofantrine

  Artemisinin derivatives   Artemisinin, artemether, artesunate,\
                            arteether

  Antimetabolites           Proguanil, pyrimethamine, atovaquone,\
                            dapsone

  Antibiotics               Tetracycline, doxycycline, minocycline

  Diaminopyridines          Pyrimethamine
  ------------------------------------------------------------------

###### Classification of neurological manifestations.

  ------------------------------------------------------------------
  Category                Specific symptoms
  ----------------------- ------------------------------------------
  Psychiatric disorders   Suicidality, violence, hallucinations,\
                          delusions, psychosis, depression,\
                          phobias, anxiety, anorexia

  Mild neurological\      Stupor, dizziness, fainting, confusion
  perturbations           

  Motor impairment        Motor impairments, ataxia

  Sleep disturbances      Nightmares, vivid dreams, insomnia,\
                          sleep pattern disturbance

  Personality changes     Mood changes, altered esteem,\
                          personality changes

  Sensory impairments     Peripheral neuropathy, anorexia,\
                          paraesthesia

  Seizures                Convulsions, seizures

  Headache                Headache

  Hearing and balance     Hearing loss, tinnitus, vertigo

  Visual                  Blurred vision, diplopia, loss of vision

  Cognition               Altered memory, concentration\
                          problems, speech problems
  ------------------------------------------------------------------

Eligible English articles were considered and articles in French, Dutch, Chinese, Hebrew, Spanish, and German were also retrieved, translated and reviewed for eligibility. Unpublished work and proceedings from scientific conferences were included in the review if they fulfilled the criteria above. There were no restrictions on dates of earliest possible publications, but articles published up to 14 ^th^ July 2016, which was the last search date, were included. Excluded from the analysis were commentaries and conference abstracts without full length and duplicate publications, as were studies of special duplicate populations ^[@ref-21]^.

Data extraction
---------------

Data was extracted into a Microsoft Excel spreadsheet with a list of variables ( [Supplementary Table 2](#SM1){ref-type="supplementary-material"}) determined *a priori* by the authors. The template was piloted on ten randomly selected studies that satisfied the inclusion criteria. The extraction was performed manually included a two-stage process: first, a determination of eligibility based on titles and abstracts; second, determination of eligibility after reviewing the full texts.

Eligibility assessment was performed independently in a standardized manner by MAB under the guidance of SMK and CRN. All articles were reviewed by at least two authors. Disagreements between reviewers were resolved by consensus. Follow-up time was defined as the number of days between administration of the antimalarial agent and the appearance of the mental and neurological symptoms.

Where overall prevalence was not reported, but an *n* (number of people reporting a specific symptom) was assigned for each mental and neurological symptom, we took the symptom for which *n* had the highest value and calculated the overall prevalence using the formula ( *n*/N)\*100; where N= total sample size of the study. The assumption was that the symptoms were not mutually exclusive. The extracted information contained Population, Interventions/treatment, Comparison groups, and Outcomes (PICO) ^[@ref-21]^. Of the 120 studies in languages other than English, retrieval and translation was only possible for 12 full articles. [Figure 1](#f1){ref-type="fig"} illustrates the selection process ^[@ref-23]^.

Classification of mental and neurological symptoms
--------------------------------------------------

Anti-malarial drug effects of the eight classes of antimalarial drugs were studied under ( [Table 1](#T1){ref-type="table"}). Specific mental and neurological symptoms were classified into 12 categories of related symptoms ( [Table 2](#T2){ref-type="table"}).

Critical appraisal of studies included in meta-analysis
-------------------------------------------------------

The quality of all observational studies that met the inclusion criteria was investigated using the The Joanna Briggs Institute Prevalence Critical Appraisal Tool ^[@ref-24]^. The tool is a ten question questionnaire with four possible responses: yes, no, unclear or not applicable. Scores of quality were calculated as a percentage, with ten as the denominator unless a section was marked as 'not applicable', in which case we excluded that section from the total quality score. This was done to avoid downgrading the total score of quality by a domain that does not apply to that study. Each positive (yes) response to a domain was equal to one point, whereas a negative response (no/unclear) attracted no point. For experimental studies, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used ^[@ref-25]^. Studies which fulfilled \>80% of the criteria for quality were included in this review.

Statistical analysis
--------------------

We computed crude median prevalence of mental and neurological manifestations expressed per 100 subjects or as a percentage and the corresponding interquartile ranges (IQR). Prevalence of mental and neurological manifestations was determined for human studies only. The 95% confidence interval (95%CI) for each study's prevalence of mental and neurological outcomes were calculated using the formula: $p \pm \lbrack 1.96\, \times \,\sqrt{p(100\, - \, p)}\rbrack/N$; where p is the prevalence as a percentage and N is the sample size ^[@ref-26]^. For unweighted pooled median prevalence of mental and neurological manifestations, we fitted a random effect model to the individual study prevalence estimates and their corresponding 95%CI using STATA version 13.1 (Stata Corp, Texas, USA). Random effect models allow effect estimates to vary across the studies. The pooled estimates from this model and their corresponding 95%CIs were obtained on the original prevalence scale. These estimates were also summarised in a forest plot ( [Figure 2](#f2){ref-type="fig"}). Comparison of the spectrum of mental and neurological manifestations and/or their severities across treatment groups was done with Persons Chi-square test or Fishers exact test, where appropriate. Comparison of prevalence between those on antimalarial drugs and controls not on antimalarial drugs was done using Pearson's Chi-square test.

The Cochrane Q-statistic was used to test the null hypothesis that the prevalence of mental and neurological manifestations was uniform across the studies. The degree of heterogeneity (I ^2^) of the pooled estimates was derived from the random effect models as a function of the Q statistics and degrees of freedom, expressed as a percentage (\[Q-df/Q\] × 100). We further investigated the contribution of factors, such as age, study design and malaria status, to the variation in the documented prevalence of mental and neurological outcomes. This was implemented by fitting two random effect meta-regression models, one as a null model without the covariates of interest and another with the variables of interest, both models with the documented prevalence as the dependent variable and the associated standard errors specified. The proportion of variation explained by the covariates studied was determined by dividing the difference in components of variance between the two models (τ0 ^2^ − τ ^2^) by the variance in the null model (τ0 ^2^). Where two variables showed strong multi-collinearity, one was picked at random for inclusion in the multivariable model. Reporting and publication ( [Figure 3](#f3){ref-type="fig"}) bias were examined in STATA using funnel plots.

Results
=======

Search results and study characteristics
----------------------------------------

The initial search yielded 2349 results, of which 596 were retained for full review based on title and abstract examination ( [Figure 1](#f1){ref-type="fig"}). After full text review, we excluded 545 articles in the quantitative analysis: articles in foreign languages for which translation could not be obtained (N=108); articles that did not mention neurotoxic outcomes (N=341); reviews (N=16) and case reports (N=80). A total of 51 studies with a reporting on 205,175 subjects were retained. The study characteristics are defined in [Table 3](#T3){ref-type="table"}.

![Study selection process.](wellcomeopenres-2-12747-g0000){#f1}

###### Description of study characteristics.

  ------------------------------------------------------------------------------------------------------------------------
  First author (Ref)             Year   Country       Design          Sample\   Malaria\   Region   Children/\   Sex (%\
                                                                      size      study               Adult        female)
  ------------------------------ ------ ------------- --------------- --------- ---------- -------- ------------ ---------
  Sjowall J ^[@ref-27]^          2012   Sweden        Randomized\     15        No         High\    Adult        40.0
                                                      control trial                        income                

  Scott UI ^[@ref-28]^           2014   USA           Randomized\     33        No         High\    Adult        36.4
                                                      control trial                        income                

  Frey SG ^[@ref-9]^             2010   Cameroon      Survey          213       Yes        Low\     Child        51.2
                                                                                           income                

  Wells TS ^[@ref-29]^           2006   Japan         Cohort          8858      No         High\    Adult        0.0
                                                                                           income                

  Pasadhika S ^[@ref-10]^        2010   USA           Randomized\     16        No         High\    Adult        100.0
                                                      control trial                        income                

  Van-riemsdijk MM ^[@ref-30]^   2004   Netherlands   Cohort          151       No         High\    Adult        57.1
                                                                                           income                

  Bhatia MS ^[@ref-31]^          1995   India         Cohort          30        No         Low\     Adult        Absent
                                                                                           income                

  Potasman I ^[@ref-32]^         2000   Israel        Survey          1340      No         High\    Adult        54.7
                                                                                           income                

  Ter Kuile FO ^[@ref-33]^       1995   Thailand      Cohort          3673      No         High\    Adult        37.6
                                                                                           income                

  Corbett El ^[@ref-34]^         1996   Britain       Survey          255       No         High\    Adult        Absent
                                                                                           income                

  Barrett PJ ^[@ref-35]^         1996   Britain       Cohort          2395      No         High\    Adult        58.1
                                                                                           income                

  Beny A ^[@ref-5]^              2001   Israel        Survey          15        No         High\    Adult        33.3
                                                                                           income                

  Gump DW ^[@ref-36]^            1977   USA           Randomized\     60        No         High\    Adult        100.0
                                                      control trial                        income                

  Wang H ^[@ref-37]^             2014   China         Randomized\     100       No         High\    Adult        53.0
                                                      control trial                        income                

  Schneider C ^[@ref-38]^        2013   Switzerland   Cohort          952       No         High\    Adult        66.5
                                                                                           income                

  Biswas PS ^[@ref-39]^          2014   India         Cohort          51        No         Low\     Adult        50.0
                                                                                           income                

  Sheehy TW ^[@ref-40]^          1967   Vietnam       Randomized\     155       No         Low\     Adult        0.0
                                                      control trial                        income                

  Thisted RA ^[@ref-6]^          2006   USA           Randomized\     31        No         High\    Adult        17.0
                                                      control trial                        income                

  Aarnoudse Al ^[@ref-41]^       2006   Absent        Cohort          89        No         Absent   Adult        46.1

  Van-riemsdijk MM ^[@ref-42]^   2002   Netherlands   Cohort          179       No         High\    Adult        46.9
                                                                                           income                

  Bhatia MS ^[@ref-31]^          1994   India         Randomized\     30        No         High\    Adult        Absent
                                                      control trial                        income                

  Ringqvist A ^[@ref-43]^        2014   Denmark       Cohort          73        No         High\    Adult        54.8
                                                                                           income                

  Loeb MB ^[@ref-44]^            2004   Canada        Randomized\     51        No         High\    Adult        58.8
                                                      control trial                        income                

  Held TH ^[@ref-45]^            1991   Germany       Randomized\     20        No         High\    Adult        Absent
                                                      control trial                        income                

  Adjei GO ^[@ref-46]^           2008   Ghana         Randomized\     227       Yes        High\    Child        47.6
                                                      trial                                income                

  Briand V ^[@ref-47]^           2009   Benin         Randomized\     1609      No         Low\     Adult        100
                                                      trial                                income                

  Vugt MV ^[@ref-48]^            2000   Thailand      Case control    158       No         High\    Mixed        29.1
                                                                                           income                

  Aceng JR ^[@ref-49]^           2005   Uganda        Randomized\     103       Yes        Low\     Child        Absent
                                                      trial                                income                

  Adam I ^[@ref-50]^             2005   Sudan         Randomized\     60        Yes        Low\     Adult        56.7
                                                      trial                                income                

  Toovey S ^[@ref-51]^           2003   Mozambique    Case control    300       Yes        Low\     Adult        1.3
                                                                                           income                

  Tange RA ^[@ref-52]^           1997   Netherlands   Case control    21        Yes        High\    Adult        38.1
                                                                                           income                

  Pasvol G ^[@ref-53]^           1991   Kenya         Randomized\     59        Yes        Low\     Child        Absent
                                                      trial                                income                

  Schlagenhauf P ^[@ref-54]^     2003   Multiple      Randomized\     623       No         High\    Adult        Absent
                                                      trial                                income                

  Vugt MV ^[@ref-55]^            1998   Thailand      Randomized\     617       Yes        High\    Mixed        31.8
                                                      trial                                income                

  Ekue JMK ^[@ref-56]^           1983   Zambia        Randomized\     98        Yes        Low\     Mixed        0
                                                      trial                                income                

  Price R ^[@ref-57]^            1999   Thailand      Randomized\     4965      Yes        High\    Mixed        43.7
                                                      trial                                income                

  Overbosch D ^[@ref-58]^        2001   Multiple      Randomized\     976       No         Low\     Mixed        45
                                                      trial                                income                

  Anh TK ^[@ref-59]^             1990   Vietnam       Randomized\     240       Yes        Low\     Mixed        0
                                                      trial                                income                

  Bunnag D ^[@ref-60]^           1996   Thailand      Comparative\    120       Yes        High\    Adult        Absent
                                                      study                                income                

  Ndam-Denoeud L ^[@ref-61]^     2012   Benin         Cohort          524       No         Low\     Adult        0
                                                                                           income                

  Harinasuta T ^[@ref-62]^       1985   Thailand      Randomized\     40        Yes        High\    Mixed        40
                                                      trial                                income                

  Mohanty AK ^[@ref-63]^         2004   India         Randomized\     80        Yes        Low\     Child        42
                                                      control trial                        income                

  Potasman I ^[@ref-64]^         2002   Israel        Randomized\     90        No         High\    Adult        54.6
                                                      control trial                        income                

  Rendi-Wagner P ^[@ref-65]^     2002   Austria       Randomized\     22        No         High\    Adult        52.5
                                                      trial                                income                

  Steffen R ^[@ref-66]^          1993   Europe        Survey          139164    No         High\    Mixed        70
                                                                                           income                

  Van-riemsdijk MM ^[@ref-67]^   2005   Netherlands   Case control\   800       No         High\    Adult        Absent
                                                      study                                income                

  Meier CR ^[@ref-68]^           2004   UK            Case control\   35370     No         High\    Adult        37.8
                                                      study                                income                

  Van Riemsdijk MM ^[@ref-7]^    2002   Netherlands   Randomized\     119       No         High\    Adult        Absent
                                                      control trial                        income                

  Andersson H ^[@ref-69]^        2008   Sweden        Survey          1170      No         High\    Adult        4.8
                                                                                           income                

  Adshead S ^[@ref-70]^          2014   UK            Survey          111       No         High\    Adult        87.5
                                                                                           income                
  ------------------------------------------------------------------------------------------------------------------------

There were 5 studies on children (\<18 years) with a total sample size of 682 (3.4%). The remaining studies were either studies on adults or mixed populations with a population of 205,175. The male and female sex ratio in the studies was well balanced (P=0.357). The median follow up time was 8 days (IQR, 3--28) for the studies that reported follow up data.

Estimates of overall prevalence and heterogeneity
-------------------------------------------------

Of the 51 eligible studies, 48 (94.9%) reported a prevalence of at least one category of mental and neurological outcomes. The estimated range of pooled prevalence of mental and neurological manifestation following antimalarial drug use from the random effect models of all the studies was between 0.7% (95%CI 0.62--1.91) for primaquine and dapsone users to 48.3% (95%CI 35.7--61.0) for minocycline users. The random effect model of the pooled prevalence across all human studies was associated with a very high between-study heterogeneity (Q=10.94, I ^2^=97.8%). There were only two studies (N=229) in which controls were persons who were not taking any antimalarial drugs ^[@ref-48],\ [@ref-51]^. In these two studies, the average prevalence of mental and neurological manifestations was 3.0%.

![Forest plot of the prevalence of mental and neurological manifestations in studies included in the meta-analysis.](wellcomeopenres-2-12747-g0001){#f2}

Factors explaining the variation in documented overall prevalence
-----------------------------------------------------------------

Several factors were assessed in the univariable analysis of human studies, and five appeared to explain the highest variation in the documented median prevalence, but none reached statistical significance level of P\<0.05 ( [Table 4](#T4){ref-type="table"}). In the multivariable meta-regression analysis, the number of drugs used was independently associated with the prevalence of mental and neurological outcomes (Prevalence ratio=5.51 \[95% CI, 1.05--29.04\], P=0.045). Other factors, such as being a child and having an acute malarial illness, were not associated with variation in prevalence of mental and neurological outcomes. The factors investigated in the multivariable analysis explained 14.1% variability of the prevalence across all human studies. In the multivariable linear regression model, there was no evidence for interaction between malaria illness and the number of drugs in explaining the variation in prevalence of symptoms (interaction parameter: beta co-efficient=2.38 \[95%CI, 0.15--37.32; P=0.503\]).

###### Heterogeneity and associated factors.

  ---------------------------------------------------------------------------------------------------------------
  Factor                      Univariable analysis   Multivariable analysis                               
  --------------------------- ---------------------- ------------------------ ------ -------------------- -------
  Year of publication         1.04 (0.99--1.1)       0.125                    4.3    0.74 (0.39--1.41)    0.789

  Study design                0.91 (0.71--1.15)      0.407                    1.2    0.84 (0.45--1.56)    0.372

  Malaria *vs* prophylaxis\   0.99 (0.21--4.71)      0.988                    23.4   2.38 (0.15--37.32)   0.663
  study                                                                                                   

  Paediatric study            1.05 (0.18--6.02)      0.955                    2.9    0.87 (0.04--19.73)   0.945

  Number of drugs             1.11 (0.62--2.00)      0.719                    0.9    5.51 (1.05--29.04)   0.045
  ---------------------------------------------------------------------------------------------------------------

Pooled prevalence of mental and neurological manifestations of individual antimalarial drugs
--------------------------------------------------------------------------------------------

The highest pooled prevalence of mental and neurological manifestations in the prophylaxis group was reported in those on sulphadoxine (55.0%; 95%CI 52.6--57.4) followed by minocycline (48.3%; 95%CI 35.7--61.0). In the treatment groups, patients receiving amodiaquine reported the highest prevalence (42.7%; 95%CI 36.3--49.2) followed by those on lumefantrine (29.5%; 95%CI 27.0--32.0) ( [Table 5](#T5){ref-type="table"}). The lowest overall prevalence was reported by dapsone and primaquine users (0.7%; 95%CI 0.6--1.9), while for prophylaxis it was 0.6% (95%CI 0.2--1.4; pyrimethamine) and for malaria studies it was 0.7% (95%CI 0.6--1.9; quinine, primaquine and dapsone).

###### Overall pooled prevalence of mental and neurological manifestations for individual drugs.

  -----------------------------------------------------------------------------
  Antimalarial\   Estimated\            Median overall\     Median overall\
  drug            percentage pooled\    prevalence in\      prevalence in\
                  median prevalence\    prophylaxis\        malaria studies\
                  with corresponding\   studies (95%CI)     c(95%CI)
                  95%CI                                     
  --------------- --------------------- ------------------- -------------------
  Amodiaquine     42.7 (36.3--49.2)     \-                  42.7 (36.3--49.2)

  Artemether      1.1 (0.9--1.4)        2.4 (0.5--4.3)      1.1 (0.9--1.4)

  Artesunate      1.1 (0.9--1.3)        1.9 (0.2--4.0)      1.1 (0.8--1.3)

  Atovaquone      8.0 (7.3--8.7)        8.7 (8.0--9.4)      8.0 (7.3--8.7)

  Chloroquine     7.1 (7.0--7.2)        7.1 (7.0--7.2)      4.9 (1.9--7.8)

  Dapsone         0.7 (0.6--1.9)        0.7 (0.6--1.9)      \-

  Doxycycline     1.6 (1.5--1.8)        1.6 (1.5--1.8)      \-

  Lumefantrine    29.5 (27.0--32.0)     \-                  29.5 (27.0--32.0)

  Mefloquine      1.9 (1.6--2.1)        25.0 (23.8--26.3)   1.0 (0.7--1.2)

  Minocycline     48.3 (35.7--61.0)     48.3 (35.7--61.0)   \-

  Primaquine      0.7 (0.6--1.9)        0.6 (0.6--1.9)      \-

  Proguanil       7.3 (7.2--7.4)        7.3 (7.2--7.4)      \-

  Pyrimethamine   20.8 (20.6--21.0)     22.3 (22.0--22.5)   0.6 (0.2--1.4)

  Quinidine       16.1 (3.2--29.1)      16.1 (3.2--29.1)    \-

  Quinine         1.7 (0.5--2.9)        0.7 (0.6--1.9)      9.3 (5.9--12.7)

  Sulfadoxine     6.0 (5.2--6.8)        55.0 (52.6--57.4)   0.6 (0.1--1.4)
  -----------------------------------------------------------------------------

\- No observations

Spectrum of mental and neurological effects
-------------------------------------------

For all the studies that reported the number of subjects with specific mental and neurological symptoms (N=205,120), headache was the most frequent symptom (N=30,726; 15.0%), followed by dizziness (N=28,626; 14.0%); neither being mutually exclusive of other mental and neurological outcomes. For studies of acute treatment of malaria, the commonest mental and neurological manifestations were hearing and balance problems (N=184; 2.6%). For prophylactic studies, the commonest manifestations were headaches (N=30,709; 15.5%) and dizziness (N=28,472; 14.4%).

Individual drugs and domains of mental and neurological outcomes
----------------------------------------------------------------

***(a) Malaria treatment studies***. Mefloquine and quinine were associated with mental and neurological manifestations in more of the domains (6 out of 10) investigated than any other antimalarial drug. Mild neurological perturbations were the most commonly reported symptom in all individual drugs studied, except amodiaquine, with the highest prevalence being in lumefantrine (10.8%). Cognition problems were infrequently reported in malaria treatment studies ( [Table 6](#T6){ref-type="table"}).

###### Mental and neurological outcomes for individual drugs by malaria treatment studies.

-No observations.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                  Psychiatric/\   Mild\           Motor\      Sleep pattern\   Personality\   Seizures   Headache    Hearing &\   Visual\    Cognition\
                        behavioural     neurological\   problems    disturbances     changes                               balance\     problems   problems
                                        perturbations                                                                      problems                
  --------------------- --------------- --------------- ----------- ---------------- -------------- ---------- ----------- ------------ ---------- ------------
  **Mefloquine,**\      2 (0.03)        136 (2.16)      40 (0.64)   114 (1.81)       1 (0.02)       1 (0.02)   \-          \-           \-         \-
  **N=6293 (%)**                                                                                                                                   

  **Chloroquine,**\     2 (1.06)        14 (7.41)       \-          \-               1 (0.53)       1 (0.53)   \-          \-           \-         \-
  **N=189 (%)**                                                                                                                                    

  **Sulfadoxine,**\     2 (0.59)        9 (2.65)        \-          \-               \-             \-         1 (0.29)    \-           \-         \-
  **N=340 (%)**                                                                                                                                    

  **Pyrimethamine,**\   2 (0.59)        9 (2.65)        \-          \-               \-             \-         1 (0.29)    \-           \-         \-
  **N=340 (%)**                                                                                                                                    

  **Artemether,**\      \-              123 (1.94)      40 (0.63)   114 (1.80)       \-             \-         \-          150 (2.37)   \-         \-
  **N=6332 (%)**                                                                                                                                   

  **Artesunate,**\      \-              136 (2.16)      40 (0.64)   114 (1.81)       \-             \-         16 (0.25)   8 (0.13)     1 (0.02)   \-
  **N=6282 (%)**                                                                                                                                   

  **Quinine, N=263**\   \-              8 (3.04)        10 (3.80)   \-               \-             5 (1.90)   16 (6.08)   34 (12.93)   1 (0.38)   \-
  **(%)**                                                                                                                                          

  **Lumefantrine,**\    \-              123 (10.75)     40 (3.50)   114 (9.97)       \-             \-         \-          150\         \-         \-
  **N=1144 (%)**                                                                                                           (13.11)                 

  **Amodiaquine,**\     **-**           **-**           **-**       **-**            **-**          **-**      **-**       **-**        **-**      **-**
  **N=227 (%)**                                                                                                                                    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

***(b) Prophylaxis studies***. Mefloquine was associated with mental and neurological manifestations in 8 out of 10 domains investigated, lacking prevalence reports in only motor impairments and seizures. Chloroquine and proguanil reported 6 out of the 10 domains each ( [Table 6](#T6){ref-type="table"}). Psychiatric/behavioural problems were reported in all the drugs examined except in quinidine and minocycline, with the highest prevalence being in atovaquone (30.7%) followed by pyrimethamine (4.7%). The lowest prevalence of psychiatric symptoms was in sulfadoxine users (0.1%). There were no reports of seizures and/or motor impairments in groups using antimalarial drugs for prophylaxis. The prevalence of mental and neurological manifestations did not differ across categories of dosage (Χ ^2^=4.65, P=0.460). [Table 7](#T7){ref-type="table"} summarizes these findings.

###### Mental and neurological outcomes for individual drugs for prophylaxis studies.

\- No observations.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                  Psychiatric/\   Mild\           Motor\     Sleep\          Personality\   Seizures   Headache        Hearing &\   Visual\         Cognition\
                        behavioural     neurological\   problems   pattern\        changes                                   balance\     problems        problems
                                        perturbations              disturbances                                              problems                     
  --------------------- --------------- --------------- ---------- --------------- -------------- ---------- --------------- ------------ --------------- ------------
  **Atovaquone,**\      819 (30.67)     54 (2.02)       \-         179 (6.70)      \-             \-         51 (1.91)       \-           24 (0.90)       \-
  **N=2670 (%)**                                                                                                                                          

  **Mefloquine,**\      8146 (4.11)     28699 (14.50)   \-         23630 (11.94)   9 (0.00)       \-         30697 (15.51)   4 (0.00)     14321 (7.235)   53 (0.03)
  **N=197959 (%)**                                                                                                                                        

  **Primaquine,**\      1 (0.65)        \-              \-         \-              \-             \-         \-              \-                           \-
  **N=155 (%)**                                                                                                                                           

  **Pyrimethamine,**\   6600 (4.69)     28094 (19.96)   \-         23280 (16.54)   \-             \-         30593\          \-           14297\          \-
  **N=140773 (%)**                                                                                           (21.73)                      (10.16)         

  **Chloroquine,**\     7985 (4.43)     28140 (15.61)   \-         22456 (12.45)   \-             \-         30593\          \-           14297\          25 (0.01)
  **N=180314 (%)**                                                                                           (16.97)                      (7.93)          

  **Proguanil,**\       8060 (4.46)     28194 (15.61)   \-         22635 (12.54)   \-             \-         30644\          \-           14321\          25 (0.01)
  **N=180571 (%)**                                                                                           (16.97)                      (7.93)          

  **Sulfadoxine,**\     1 (0.06)        \-              \-         885 (55.00)     \-             \-         \-              \-           \-              \-
  **N=1609 (%)**                                                                                                                                          

  **Quinine, N=160**\   1(0.63)         \-              \-         \-              \-             \-         \-              \-           \-              \-
  **(%)**                                                                                                                                                 

  **Dapsone,**\         1 (0.65)        \-              \-         \-              \-             \-         \-              \-           \-              \-
  **N=155 (%)**                                                                                                                                           

  **Doxycycline,**\     578 (1.60)      \-              \-         8 (0.02)        \-             \-         \-              \-           \-              \-
  **N=36077 (%)**                                                                                                                                         

  **Quinidine,**\       \-              5 (16.13)       \-         3 (9.68)        \-             \-         4 (12.90)       1 (3.23)     \-              \-
  **N=31(%)**                                                                                                                                             

  **Minocycline,**\     \-              \-              \-         \-              58 (48.33)     \-         44 (36.67)      6 (5.00)     \-              48 (40.00)
  **N=120 (%)**                                                                                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion
==========

The pooled estimates from this study show that the prevalence of mental and neurological manifestations differ with antimalarial drugs, as well as malaria status, of individuals using these drugs. The range of overall prevalence is higher in the absence of acute malaria (0.6--42.7% *vs* 0.7--55.0%). Similar to previous reports ^[@ref-71]^, minocycline had the highest prevalence of mental and neurological outcomes (48.3%) and artesunate had the lowest (1.1%). Headaches and dizziness are the most frequent manifestations, and symptoms for psychiatric disorders and cognitive impairment were common with malaria prophylaxis. The number of antimalarial drugs used independently explained the variation in documented overall prevalence. While sulphadoxine and minocycline contributed the highest prevalence of mental and neurological manifestations, mefloquine affected the most domains assessed. These results are based on few human studies (N=51) out of 2,349 abstracts initially identified, suggesting a significant research gap with regards to evaluation of antimalarial drugs for mental and neurological outcomes in humans.

Prevalence and heterogeneity
----------------------------

The pooled prevalence of mental and neurological manifestations is robust and accounts for heterogeneity between studies, unlike descriptive median estimates, which would otherwise underestimate the true prevalence. The pooled estimates compare favourably with those of some randomised studies, although these studies focused on fewer drugs ^[@ref-37],\ [@ref-49]^. Headaches and dizziness were the most common symptoms, and particularly those on prophylactic treatment, and are often asked for or assessed during studies. Mental and neurological manifestations of the drugs were evaluated in the short-term for most studies (median follow-up, 10 days; IQR, 5--21 days), so this may underestimate prevalence of conditions, such as epilepsy, which take time to develop following neurotoxicity ^[@ref-65],\ [@ref-72],\ [@ref-73]^. This may explain why some domains, such as seizures and motor impairments, were infrequently documented following prophylaxis. There were no reports of cognition problems in malaria studies probably because neurocognition data during the acute phase of malaria may go undocumented due to misattribution of poor cognition to malaria disease, rather than the drugs used to treat the disease, or perhaps because neuropsychological tests are performed following recovery from the episode of acute malaria. The heterogeneity was greater than 70%, usually considered as the proportion attributable to between studies heterogeneity. The excess heterogeneity may be related to bias from publication, reporting and selection, as supported by some studies plotting outside the funnel outline in the meta-funnel analysis as shown in [Figure 3](#f3){ref-type="fig"}.

Most negative studies may be unpublished, since majority of the eligible studies reported at least one domain of mental and neurological manifestations. There was between study variations in the methods of assessment of mental and neurological manifestations which may have contributed to the heterogeneity of pooled estimates observed during the analysis. This informed our decision to apply the random effect model rather than the fixed effect model during analysis.

![A funnel plot of bias of the selected studies.](wellcomeopenres-2-12747-g0002){#f3}

Factors explaining variation in prevalence of mental and neurological manifestations
------------------------------------------------------------------------------------

We investigated the contribution of five factors (decided by the authors *a priori*) to the variation in prevalence of mental and neurological manifestations, and found that an increasing number of drug combinations were associated with mental and neurological manifestations. The five factors investigated only explained 14% of the variability in prevalence, and it is possible the prevalence is in part dependent upon other factors unreported in the included studies. These factors may include levels of endemicity of malaria in the study sites and individual factors such as resistance to malaria, which may vary across the eligible studies. The random effects model that we applied for the meta-analysis allowed effect estimates of mental and neurological manifestations to vary across the sites. While the World Health Organization (WHO) recommends a maximum of two drugs in combination therapies aimed at reducing development of resistance to newer drugs, such as artemesinin derivatives (WHO guidelines for malaria treatment), three drug combinations were common (30%) in many studies identified by this review. Although combinations of antimalarials are used to increase efficacy, prevent transmission and reduce resistance, such combinations may increase levels of mental and neurological manifestations, probably from cumulative toxicity of individual drugs. The number of drugs may also be a surrogate marker of possible neurotoxcity, since the two were highly correlated. There was no evidence of interaction between the number of drugs and malaria status/illness, with regard to prevalence of mental and neurological manifestations. Age group was not associated with prevalence of mental and neurological manifestations, although there were significantly fewer children compared to adults in this analysis, yet children bear the brunt for malaria morbidity and mortality in Africa. Ethical considerations may in part explain fewer children participants in the studies, as early-phase clinical trials usually exclude children. The lack of association with year of study may highlight lack of new studies in recent years compared to earlier years, justifying the need for recognition of the problem through conduct of more future studies.

Mental and neurological manifestations and individual antimalarial drugs
------------------------------------------------------------------------

For prophylactic studies, sulfadoxine and minocycline were associated with the highest prevalence of mental and neurological manifestations. For acute malaria studies, hydroxychloroquine was associated with the highest prevalence of mental neurological manifestations. This finding is important as some of these drugs are routinely being used for the treatment of malaria according to WHO recommendations in the guidelines for the treatment of malaria ^[@ref-72],\ [@ref-74],\ [@ref-75]^. Antibiotics, such as doxycycline and tetracycline, which were associated with some mental and neurological manifestations, are often combined with other drugs in 2 ^nd^ line regimens for uncomplicated malaria ^[@ref-76],\ [@ref-77]^, while clindamycin is used during pregnancy ^[@ref-78],\ [@ref-79]^. However, it is important to note that data provided on minocycline are based on one study only and, as Dr Grabias and Dr. Remington noted in their reviews on psychiatric effects of malaria and antimalarials, psychiatric reports following tetracycline use in malaria is almost non-existent ^[@ref-74],\ [@ref-75]^. Artemisinin derivatives are the drugs of choice for malarial treatment when combined with other therapies. Similarly, diaminopyridines, such as pyrimethamine, are combined with artesunate for first line treatment, and are used in pregnancy and prophylaxis (Guidelines for the treatment of malaria, WHO). There is however lack of sufficient studies on their safety to the foetal brain. Some drugs, such as hydroxychloroquine, are no longer routinely recommended by the WHO for use in the management of malaria ^[@ref-80]^, although they are still widely used in the rheumatology community ^[@ref-81]^. Although drugs, such as minocycline, are not in routinely used as an antimalarial, they are still used for conditions, such as acne, for which patients on the drug may benefit from evaluation of mental and neurological status. The low prevalence of mental and neurological manifestations with artemether and artesunate are reassuring, since these are the mainstay drugs for the management of falciparum malaria. Also no prospective studies have examined mental and neurological outcomes of artemisinin derivate use alone ^[@ref-75]^. Reassuringly, very low frequencies were observed for specific domains of neurological manifestation supporting the safety profile of artemether and artesunate. It is however worth noting that this conclusion may be biased since artemether and artesunate are recent drugs for which adverse events are yet to be exhaustively studied. Mefloquine toxicity has been the subject of many case reports ^[@ref-20],\ [@ref-82]--\ [@ref-85]^. Our review however found a relatively low prevalence of mefloquine toxicity. Also, unlike a study published by Weinke and colleagues ^[@ref-86]^, our study observed higher prevalence in prophylactic use than in studies of acute treatment of malaria. However, the low prevalence from mefloquine may have been caused by the inclusion of the MALPRO observational study ^[@ref-66]^ in our meta-analysis, which contained a large sample size, although, as with artemisinin derivatives, no large randomized studies exist on psychiatric effects of mefloquine on healthy subjects.

The commonest domain affected by most drugs was mild neurological perturbations (e.g. dizziness) for malaria studies, and psychiatric or behavioural problems for prophylaxis studies. Mefloquine was associated with impairments in more domains investigated than any other antimalarial drug, probably explaining why it has been commonly mentioned in previous reviews ^[@ref-87]--\ [@ref-89]^. Psychiatric manifestations were the most reported outcomes following use of mefloquine from our present study, which is in agreement with previous findings ^[@ref-75]^. Mild neurological perturbations, such as stupor, were largely contributed by use of pyrimethamine (20%), which is still used for prophylaxis of malaria. Given that pyrimethamine is usually combined with sulphadoxine, which had the highest frequency of manifestations in an individual drug category, individuals on these drugs should be monitored closely and patients counselled appropriately. These findings highlight the importance of focusing on assessment of specific domains of mental and neurological manifestations, rather than the overall prevalence with regards to their association with antimalarial drugs.

Hypotheses of mechanisms of mental and neurological manifestations of antimalarial drugs
----------------------------------------------------------------------------------------

Animal studies have indicated that antimalarial drugs commonly affect the hind brain, which contains the reticular formation (controls transitions from sleep to consciousness), and brain stem (has cranial nerves, some innervating the head), perhaps explaining the high prevalence of dizziness and headaches in humans. For instance, mefloquine causes mental and neurological manifestations by disrupting calcium homeostasis of neuronal cells, inhibition of enzymes such as acetylcholinesterase, and blockade of intercellular channels, particularly connexion Cx36, which is a gap junction protein thought to be involved in synchronizing rhythmic activity of neurons in several brain regions ^[@ref-87]^. Chloroquine may interact with multiple neurotransmitter systems: prostaglandin-E antagonism, acetylcholine imbalance and excess dopamine are among the postulated mechanisms ^[@ref-31]^. It is possible that the mechanism of mental and neurological manifestations of antimalarials involves a complex interaction of multiple systems and more studies are required to determine the precise mechanisms by which these deleterious effects occur. The process through which anti-malarial drugs cause damage to the brain is not yet clear, but several hypotheses are proposed for specific drugs, as summarized in [Table 8](#T8){ref-type="table"}.

###### Proposed mechanisms of neurotoxicity.

  ------------------------------------------------------------------------------------------------------
  Drug          Proposed mechanisms of neurotoxicity
  ------------- ----------------------------------------------------------------------------------------
  Chloroquine   •  Sensitize cell-killing effects ^[@ref-90]^\
                •  Cerebrocortical stimulant that increases EEG frequencies ^[@ref-91]^\
                •  Prostaglandin E antagonism ^[@ref-92]^\
                •  Acetylcholinesterase inhibition ^[@ref-93]^\
                •  Depression of cortical activity ^[@ref-94]^\
                •  Inhibition of membrane calcium channels ^[@ref-95]^\
                •  Glucose 6 phosphate dehydrogenase deficiency ^[@ref-92]^\
                •  Alteration of dopamine levels ^[@ref-93]^\
                •  Induction of cholinergic imbalance ^[@ref-94]^

  Mefloquine    •  Disruption of gap junction communication and GABAergic\
                interneuron dysfunction ^[@ref-82]^\
                •  Inhibition of cellular transport ^[@ref-87]^\
                •  Disrupts direct intercellular electrical communication ^[@ref-96]^\
                •  Acetylcholinesterase inhibition ^[@ref-42]^\
                •  Primary hepatocellular injury ^[@ref-97]^\
                •  Depression of cortical activity ^[@ref-94]^

  Minocycline   •  Disrupts microglia distribution in the developing somatosensory cortex ^[@ref-98]^\
                •  Modifies electrophysiological properties of layer 5 microglia ^[@ref-98]^

  Quinine       •  Inhibits cytochrome P450-3A4 ^[@ref-99]^
  ------------------------------------------------------------------------------------------------------

Strengths and limitations
-------------------------

The study focused on all types of antimalarial drugs, which provides empirical basis for evaluating new *vs* older drugs and safety profiles of antimalarial drugs recommended by the WHO. We have used robust statistical approaches to estimate the overall prevalence, while accounting for potential heterogeneity between studies. Most of the studies are based on hospital data, which may bias results towards severity, especially for low-income countries where rate of hospital use is often low. We may have underestimated prevalence for specific domains, since some studies did not report multiple domains of mental and neurological manifestations. Our results are based on short-term evaluation of mental and neurological manifestations after antimalarial drugs, so it is unclear what the long-term effects are. Some prevalence estimates are based on a small denominator, thus studies with larger sample sizes are required in future. It is difficult to separate the mental and neurological manifestation of malarial disease from that of the drugs used to treat malaria in settings where drugs were not used for prophylaxis. Some prevalence estimates are based on observational studies rather than randomised controlled studies. As a result, it is difficult to appraise the methodology of observational studies. Additionally our meta-analysis found high between study heterogeneity, which we could not account for in our analysis. Further studies need to be done to explain the differences observed between studies. We applied a stringent quality check on all studies based on GRADE for experimental studies and The Joanna Briggs Institute Prevalence Critical Appraisal Tool for observation studies. This quality check may have excluded a number of children studies.

Conclusions
===========

This review suggests that mental and neurological manifestations may occur following antimalarial drug use. Potential adverse effects should be assessed and addressed after use of an antimalarial drugs, particularly following prophylactic use. In addition, the mental and neurological effect of antimalarials is poorly researched; few human studies were identified and most of these were not recent. Efforts to develop new effective and safer antimalarial drugs should be accelerated by scientists and development partners. Pharmacovigilance (Phase IV) studies should be set up to document the long-term effects of antimalarials.

Data availability
=================

The data referenced by this article are under copyright with the following copyright statement: Copyright: © 2017 Bitta MA et al.

The dataset used for this analysis is available on the Open Science Framework: DOI, [10.17605/OSF.IO/2RMCN](http://dx.doi.org/10.17605/OSF.IO/2RMCN) ( <https://osf.io/2rmcn/>) ^[@ref-100]^.
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This is an excellent systematic review looking at the neuropsychological and neurological side effects of anti malarial medication when provided to children. It provides some evidence through a meta-analysis of the combined evidence for side effects and the differences in side effect profiles between different antimalarial medications. 

The authors have used really clear rationale for the study and have provided a clear statement of the question that they have. The tables and supplementary files provide most of the data which is required in the PRISMA guidelines. They have very carefully explained the search strategy, the mechanisms for managing the data, the review process and extraction process and the variables assessed. 

Methodology:

The authors do mention in their results that the review included all ages of individuals however this was not entirely clear in the methods and might be worth mentioning earlier. It also was not entirely clear which settings in the world the studies were derived from. I assume from the results that the articles were not filtered at all by setting and that therefore they were derived from any setting in the world. This might be important to mention in the methods and in the results.

The authors clearly delineate the outcomes that they are studying and provide information of how they classified neurological manifestations however it was not clear as to whether the outcomes measured between the different studies were similar in terms of how they measured neuropsychiatric or neurological manifestations, e.g. in children post cerebral malaria vs adult travellers who have been given mefloquine. It might be useful to mention how data in these different studies was gathered and how comparable they were (if not in the methods then at least to discuss it in the discussion section). 

Many of the studies identified specifically mention neuropsychiatric or neurological manifestations in their results and as far as i can gather, the main aims of these studies were to identify these outcomes. Many other studies must be done to look at the efficacy and comparability of medications for treating malaria where neurological or neuropsychiatric outcomes are an \"adverse event\" but not necessarily the main crux of the study. Looking back at a review done in children by Ramos-Martin ^[@rep-ref-22085-1]^, there were 15 studies reviewed with children where outcomes relating to ototoxicity were identified. The authors in the present study have only identified 5 studies in children. I was not sure if that was to do with the inclusion criteria  or criteria for quality of studies in this present study or whether it just needed to be clearer that they were only identifying studies where the main aim was to look at neuropsychiatric or neurological outcomes. If so, it might be worth mentioning that in the discussion as a limitation. 

The authors lump the studies together even though the studies are of very different types, are from different populations (e.g. persons of different age groups, living in different places with different levels of endemicity of malaria, persons who are likely to have some resistance to malaria vs those who do not, different dosages of medications being provided, treatment being for children with cerebral malaria vs adult travellers prophylactically vs symptomatic uncomplicated malaria in children). It might be useful again in the discussion to mention the large heterogeneity in the populations studied which therefore must create some limitations to the data. Despite this there seem to be some trends that emerge that are helpful to share with the scientific community.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
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Dear Dr Gladstone

Thank you for reviewing our article.  We have considered your recommendations and addressed them in the manuscript as follows:

  We have clarified in the inclusion/exclusion criteria that the eligible studies were not filtered by study settings.We have noted in the discussion section that the different methods of assessment of neurological and mental manifestations in individual eligible studies may have contributed to the heterogeneity of pooled estimates observed during the analysis which informed our decision to apply the random effect model rather than the fixed effect model. The random effect model allows the prevalence of mental and neurological manifestations varies from one study to the next.We have noted in the limitation section that a quality check on all eligible studies was performed which may have excluded a number of children studies. We already described in the methods section of first version that the quality check was based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system for experimental studies and The Joanna Briggs Institute Prevalence Critical Appraisal Tool for observation studies.. We have now noted in the discussion session that the very high between study heterogeneity observed may be partly explained by factors not reported in the included studies such as levels of endemicity of malaria in the study sites and individual factors such as resistance to malaria, as suggested by the reviewer.
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Very good and interesting manuscript.  The title is appropriate;The abstract is an adequate summary of the article;The methods are comprehensive;The conclusions are balanced and justified I have nothing to suggest.
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